基于ICRP141号报告模型计算吸入241Am后的排泄份额及剂量的对比分析

依据更丰富的受照人员实测数据,以国际放射防护委员会(ICRP)141号报告呼吸道模型及系统模型为代表的新模型及剂量转换系数相比旧模型及剂量转换系数具有更高可信度。对于目前超铀核素吸入后的基于间接测量的内照射评价来说,新、旧模型带来的计算结果的异同很重要。本文基于ICRP 141号报告为代表的新生物动力学模型建立超铀核素的滞留、排泄份额计算程序,并分别对工作参考人吸入S、M、F类²⁴¹Am气溶胶(AMAD 5 μm)后的尿、粪排泄份额进行新、旧模型计算值对比,发现了新、旧模型计算值的显著差异,且基于尿、粪样中²⁴¹Am估算有效剂量上,新、旧模型计算结果的差异也显著。基于尿粪的间接测量的内照射评价标准后期可视情况根据新模型计算值进行修订。

The comparison and analysis of excretion fraction after inhalation of 241Am based on ICRP No.141 biokinetic model

Based on more advanced techniques and wider range of internal dose monitoring data from exposed human, the new biokinetic models (such as HRTM and Systematic Model) and dose convention coefficients from ICRP No.141 Publication will give us additional confidence in the data provided. The difference and similarity of the new and old models calculation results are very important for internal dose evaluation from excreta monitoring of transuranic elements inhaled. The excretion fraction calculating program of the transuranic elements' new biokinetic models from ICRP No.141 publication is established, then the urine and feces fraction of ²⁴¹Am in reference worker who has inhaled S,M,F type ²⁴¹Am aerosol (AMAD 5 μm) have been calculated respectively for the new models' and old models' results. The comparing of the results indicates big difference between the new and old model's excretion fraction results, and the committed effective doses calculated by the new and old models are also quite different. The internal dose evaluation criteria using excreta monitoring method can use the new model's results in some cases when needed in the near future.